Jump to content

Veronica Kinsler

From Wikipedia, the free encyclopedia
Veronica Anne Kinsler
Born
Scotland, UK
Alma materUniversity of Cambridge, University College London
Scientific career
FieldsPaediatric Dermatology, Molecular Genetics, Precision Medicine
InstitutionsFrancis Crick Institute

University College London

Great Ormond Street Hospital
Websitehttps://www.crick.ac.uk/research/find-a-researcher/veronica-kinsler

Veronica Kinsler is a British physician scientist specialising in paediatric dermatology and molecular genetics.[1] She is Professor of Paediatric Dermatology and Dermatogenetics at the Great Ormond Street Hospital for Children (GOSH) and the University College London GOS Institute of Child Health.[2]

Education and career

[edit]

Kinsler studied Medical Sciences and Clinical Medicine at the University of Cambridge, and completed a PhD in Molecular Genetics at the University College London.[3] She also received training in paediatric dermatology.[2]

Kinsler works both in clinical practice and as a researcher.[4] She is a professor of Paediatric Dermatology and Dermatogenetics at the Great Ormond Street Hospital for Children (GOSH) and the University College London GOS Institute of Child Health.[2] She also works as the Principal Group Leader and Assistant Research Director at the Francis Crick Institute in London.[3] She was the president of the European Society of Pediatric Dermatology between 2020 and 2022.[5] She is the senior editor of Harper's Textbook of Pediatric Dermatology.[3] In 2021 she was awarded a Research Professorship by the National Institute for Health and Care Research (NIHR).[6] She is a Fellow of the Royal College of Paediatrics and Child Health.[7]

Research

[edit]

Her research focuses on children's skin diseases, including rare and genetic conditions, mosaicism, and diseases that can result in cancer.[4][8] Her research led to the discovery of the genetic causes of multiple rare diseases, including congenital melanocytic naevus syndrome[4][9] and arteriovenous malformations.[10][11] Her research explores novel therapeutic approaches for currently incurable diseases.[4][12]

References

[edit]
  1. ^ "Veronica Kinsler". scholar.google.com. Retrieved 2024-02-02.
  2. ^ a b c "Veronica Kinsler MA MB BChir FRCPCH PhD". GOSH Hospital site. Retrieved 2024-02-02.
  3. ^ a b c "Veronica Kinsler". Crick. 2024-06-01. Retrieved 2024-02-02.
  4. ^ a b c d Kinsler, Veronica A. (2024-06-01). "Piecing together the mosaic of rare skin diseases: an interview with Veronica Kinsler". Disease Models & Mechanisms. 17 (6). doi:10.1242/dmm.050636. ISSN 1754-8403. PMC 10820732. PMID 38235593.
  5. ^ "History". European Society for Paediatric Dermatology. Retrieved 2024-02-03.
  6. ^ "Current NIHR Research Professors". www.nihr.ac.uk. Retrieved 2024-02-02.
  7. ^ "Veronica Kinsler". University College London. Retrieved 2024-02-03.
  8. ^ "Lecturers". Paediatric Dermatology Courses. Retrieved 2024-02-03.
  9. ^ Kinsler, Veronica A.; Thomas, Anna C.; Ishida, Miho; Bulstrode, Neil W.; Loughlin, Sam; Hing, Sandra; Chalker, Jane; McKenzie, Kathryn; Abu-Amero, Sayeda; Slater, Olga; Chanudet, Estelle; Palmer, Rodger; Morrogh, Deborah; Stanier, Philip; Healy, Eugene (September 2013). "Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS". Journal of Investigative Dermatology. 133 (9): 2229–2236. doi:10.1038/jid.2013.70. PMC 3678977. PMID 23392294.
  10. ^ "Cancer drugs could treat rare blood-vessel disorder". 2018-02-20. Retrieved 2024-02-03.
  11. ^ Al-Olabi, Lara; Polubothu, Satyamaanasa; Dowsett, Katherine; Andrews, Katrina A.; Stadnik, Paulina; Joseph, Agnel P.; Knox, Rachel; Pittman, Alan; Clark, Graeme; Baird, William; Bulstrode, Neil; Glover, Mary; Gordon, Kristiana; Hargrave, Darren; Huson, Susan M. (2018-11-01). "Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy". Journal of Clinical Investigation. 128 (11): 5185. doi:10.1172/JCI124649. ISSN 0021-9738. PMC 6205386. PMID 30382944.
  12. ^ "Breakthrough means painful, giant moles that develop in rare condition CMN could be reversed". Sky News. Retrieved 2024-11-03.
[edit]